Ruslan Duka

Prof. Dr. Ruslan Duka

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SMSilvia Malerba
Silvia Malerba
MVMiljana Vladimirov
Miljana Vladimirov
AGAman Goyal
Aman Goyal
Audrius DulskasAudrius Dulskas
Audrius Dulskas
ABAugustinas Bausys
Augustinas Bausys
Luigi MaranoLuigi Marano
Luigi Marano
Background: Artificial intelligence is emerging as a promising tool in surgical oncology, with growing evidence suggesting potential applications in diagnostic support, intraoperative guidance, and perioperative risk assessment. In gastric cancer surgery, emerging applications range from AI-assisted endoscopic detection to data-driven perioperative risk prediction, while some technological developments, particularly in robotic autonomy, derive from broader surgical or experimental models that may inform future gastric procedures. Methods: A narrative review was conducted following established methodological standards, including the Scale for the Assessment of Narrative Review Articles (SANRA) and the Search–Appraisal–Synthesis–Analysis (SALSA) framework. English-language studies indexed in PubMed, Scopus, Embase, and Web of Science up to October 2025 were included. Evidence was synthesized thematically across five domains: AI-assisted anatomical recognition and lymphadenectomy support, autonomous robotic systems, early cancer detection, perioperative predictive and frailty models, and ethical and regulatory considerations. Results: AI-based computer vision and deep learning algorithms have demonstrated promising capabilities for real-time anatomical recognition, surgical phase classification, and intraoperative guidance, although evidence of direct patient-level benefit remains limited. In diagnostic settings, AI-assisted endoscopy and Raman spectroscopy have been shown to improve early lesion detection and reduce dependence on operator experience. Predictive models, including MySurgeryRisk and AI-driven frailty assessments, may support individualized prehabilitation planning and perioperative risk stratification. Persistent limitations include small and heterogeneous datasets, insufficient external validation, and unresolved concerns related to data privacy, algorithmic interpretability, and medico-legal responsibility. Conclusions: Artificial intelligence is progressively emerging as a promising tool in gastric cancer surgery, integrating automation, advanced analytics, and human clinical reasoning. Its safe and ethical adoption requires robust validation, transparent governance, and continuous surgeon oversight. When developed within human-centered and ethically grounded frameworks, AI can augment, rather than replace, surgical expertise, potentially advancing precision, safety, and equity in oncologic care.

28 January 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
YVYogesh Kumar Vashist
Yogesh Kumar Vashist
AGAman Goyal
Aman Goyal
PSPreethi S Shetty
Preethi S Shetty
SGSergii Girnyi
Sergii Girnyi
CTCwalinski Tomasz
Cwalinski Tomasz
RORodolfo J Oviedo
Rodolfo J Oviedo
Background: Esophageal cancer, the seventh most common malignancy globally, requires esophagectomy for curative treatment. However, esophagectomy is associated with high postoperative morbidity and mortality, highlighting the need for minimally invasive approaches. Robotic-assisted surgery has emerged as a promising alternative to traditional open and minimally invasive esophagectomy (MIE), offering potential benefits in improving clinical and oncological outcomes. This review aims to assess the postoperative morbidity and outcomes of robotic surgery. Methods: A comprehensive review of the current literature was conducted, focusing on studies evaluating the role of robotic-assisted surgery in esophagectomy. Data were synthesized on the clinical outcomes, including postoperative complications, survival rates, and recovery time, as well as technological advancements in robotic surgery platforms. Studies comparing robotic-assisted esophagectomy with traditional approaches were analyzed to determine the potential advantages of robotic systems in improving surgical precision and patient outcomes. Results: Robotic-assisted esophagectomy (RAMIE) has shown significant improvements in clinical outcomes compared to open surgery and MIE, including reduced postoperative pain, less blood loss, and faster recovery. RAMIE offers enhanced thoracic access, with fewer complications than thoracotomy. The RACE technique has improved patient recovery and reduced morbidity. Fluorescence-guided technologies, including near-infrared fluorescence (NIRF), have proven valuable for sentinel node biopsy, lymphatic mapping, and angiography, helping identify critical structures and minimizing complications like anastomotic leakage and chylothorax. Despite these benefits, challenges such as the high cost of robotic systems and limited long-term data hinder broader adoption. Hybrid approaches, combining robotic and open techniques, remain common in clinical practice. Conclusions: Robotic-assisted esophagectomy offers promising advantages, including enhanced precision, reduced complications, and faster recovery, but challenges related to cost, accessibility, and evidence gaps must be addressed. The hybrid approach remains a valuable option in select clinical scenarios. Continued research, including large-scale randomized controlled trials, is necessary to further establish the role of robotic surgery as the standard treatment for resectable esophageal cancer.

31 January 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
Luigi MaranoLuigi Marano
Luigi Marano
CTCwalinski Tomasz
Cwalinski Tomasz
SGSergii Girnyi
Sergii Girnyi
Jaroslaw SkokowskiJaroslaw Skokowski
Jaroslaw Skokowski
AGAman Goyal
Aman Goyal
YVYogesh Kumar Vashist
Yogesh Kumar Vashist
Introduction: Robot-assisted minimally invasive gastrectomy (RAMIG) represents a significant advancement in the surgical management of gastric cancer, offering superior dexterity, enhanced visualization, and improved ergonomics compared to laparoscopic gastrectomy (LG). This review systematically evaluates the current evidence on perioperative outcomes, oncological efficacy, learning curves, and economic considerations, providing insights into RAMIG’s potential role in modern gastric cancer surgery. Methods: A thorough analysis of retrospective, prospective, and meta-analytic studies was conducted to compare RAMIG with LG. Key outcomes, including operative time, intraoperative blood loss, lymph node retrieval, postoperative complications, learning curve duration, and cost-effectiveness, were assessed. Emphasis was placed on both short-term and long-term oncological outcomes to determine the clinical value of RAMIG. Results: Evidence indicates that RAMIG is associated with reduced intraoperative blood loss, lower morbidity rates, and a shorter learning curve, with proficiency achieved after 11–25 cases compared to 40–60 cases for LG. The robotic platform’s articulated instruments and enhanced three-dimensional visualization enable more precise lymphadenectomy, particularly in complex anatomical regions. Despite these advantages, operative time remains longer, and costs remain higher due to system acquisition, maintenance, and consumable expenses. However, emerging data suggest a gradual narrowing of cost disparities. While short-term outcomes are favorable, further high-quality, multicenter studies are needed to validate long-term oncological efficacy and survival outcomes. Conclusion: RAMIG offers significant technical and clinical advantages over conventional LG, particularly in terms of precision and learning efficiency. However, the long-term oncological benefits and economic feasibility require further validation. Future research should focus on cost optimization, advanced technological integration such as near-infrared fluorescence and artificial intelligence, and multicenter trials to solidify RAMIG’s role as a standard approach for gastric cancer surgery.

18 July 2025 in International Journal of Surgery
Verified
Journal Article
Open access
LBLuigi Brusciano
Luigi Brusciano
ABAntonio Brillantino
Antonio Brillantino
Luigi MaranoLuigi Marano
Luigi Marano
SRStefan Riss
Stefan Riss
PGPasquale Giordano
Pasquale Giordano
LDLudovico Docimo
Ludovico Docimo
Background: Sphinkeeper™ (SK) implantation has emerged as a minimally invasive option for patients with fecal incontinence (FI) who fail to respond to conservative therapies. While preliminary outcomes have been encouraging, robust mid-term data remain limited. This study aimed to evaluate the safety, efficacy, and quality-of-life outcomes of SK implantation in a large, multicenter European cohort. Materials and methods: This retrospective cohort study included patients with FI who underwent SK implantation between 2017 and 2022 across seven tertiary referral centers in Europe. Eligible patients had failed pharmacological and pelvic floor rehabilitation therapies and completed at least 3 years of follow-up. Primary outcomes included changes in the Cleveland Clinic Incontinence Score (CCIS), Vaizey score, weekly incontinence and soiling episodes, and the ability to postpone defecation. Secondary outcomes assessed changes in the fecal incontinence quality of life (FIQoL) scale. All patients underwent standardized clinical, ultrasonographic, and manometric evaluations preoperatively and at 3 months postoperatively. Results: A total of 111 patients (61.2% female; median age 59.4 years) were included. Median CCIS decreased from 12 (range: 6–18) at baseline to 7 (1–10) at 12 months, with sustained improvement at 3 years ( P < 0.0001). Vaizey scores and weekly incontinence episodes significantly declined, while the ability to postpone defecation improved from 8 to 18 seconds ( P < 0.001). All FIQoL domains showed significant enhancement by 12 months and remained stable through 36 months. No major complications were reported, and implant positioning was confirmed as adequate in 91.9% of cases. Conclusion: SK implantation is a safe and effective treatment for refractory FI, offering durable improvements in continence, urgency control, and quality of life over a 3-year follow-up period. These findings support its role as a viable minimally invasive alternative in the contemporary management of FI.

28 June 2024 in Medicni perspektivi
Verified
Journal Article
Open access
PDF file
KBK.S. Barannik
K.S. Barannik
OIOksana Ishchenko
Oksana Ishchenko
RDRuslan Duka
Ruslan Duka
RMRobert Molchanov
Robert Molchanov
DSDmytro Stepanskyi
Dmytro Stepanskyi
The aim of the study was to analyse the microbial profile of the urinary tract infections (UTIs) due to urolithiases and to study susceptibility to antibiotics in its causative agents. The main method of the research was bacteriological. Antimicrobial susceptibility testing was conducted by serial microdilution assay in accordance with recommendations of the European committee on antimicrobial susceptibility testing (EUCAST). For present study 128 unique urine samples were collected from patients with UTIs associated with urolithiasis. Among all collected specimens, 78% (n=100) gave clinically signi­ficant growth. Among all examined participants, 88.9% of women (64/72) and 64.3% of men (36/56) had confirmed UTI; in the study, female/male ratio was 1.4 (χ2=9.76; p<0.05). Microorganisms identified in our study predominantly belon­ged to Bacteria (93.4%), and yeasts of Candida genus comprised only 6.6%. Among all, 66.1% were representatives of Enterobacterales (n=80), particularly, Escherichia coli (38.0%), Klebsiella oxytoca (15.7%), Klebsiella pneumoniae (2.5%), Enterobacter cloacae (5.8%), Proteus mirabilis (4.1%). Isolates of Pseudomonas aeruginosa comprised 3.3%. Among gram-positive isolates, Staphylococcus spp. (14.1%) and Enterococcus spp. (9.9%) were identified. Regarding female/male distribution, the biggest proportion of gram-positive bacteria were isolated from women, statistically significant results were obtained for sex distribution of S. saprophyticus (p<0.05). Antimicrobial susceptibility of Enterobacterales was variable, and the best results were obtained for carbapenems, novel antibiotics (cefiderocol, ceftolozane-tazobactam and ceftazidime-avibactam), aminoglycosides and tigecycline. There were 9 isolates with pro­duction of carbapenemases and resistant to all relevant β-lactam antibiotics. All isolated Staphylococcus spp. were β-lactamase producers, one isolate of S. saprophyticus demonstrated methicillin-resistance. To summarise, there is an ongoing outbreak of multidrug-resistant infections in Ukraine and causative agents of UTIs are among the most important contributors. Availability of data on the local antimicrobial susceptibility profile may guide the informed decision making in etiotropic treatment, therefore, contribute to global efforts in rational drug use and fight the resistance escalation.

6 November 2023
Verified
Book Chapter
Open access
PDF file
RMRobert Molchanov
Robert Molchanov
OBOleg Blyuss
Oleg Blyuss
RDRuslan Duka
Ruslan Duka
This study evaluated the use of sentinel lymph node (SLN) dissection with indocyanine green/near-infrared (ICG/NIR) technology in laparoscopic radical prostatectomy for clinically localized prostate cancer (PCa). Conducted from 2020 to 2023, the study included 60 patients: 45 at intermediate or high risk underwent both SLN dissection and extended pelvic lymph node dissection (ePLND), while 15 low-risk patients had SLN dissection only. Sentinel nodes were identified in over 90% of cases. Body mass index (BMI) was found to influence the time taken to locate SLNs. Among intermediate and high-risk patients, 22% showed metastatic involvement. The procedure demonstrated a specificity of 90%, sensitivity of 80%, and positive predictive value of 95,7%. The study concludes that SLN dissection is a feasible and effective method for preoperative nodal staging in PCa, although further research is needed for optimization.